Cubist Systematic Strategies’s Acumen Pharmaceuticals ABOS Stock Holding History

Cubist Systematic Strategies’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$40.9K	Buy	+23,904	New	+$33.1K	﹤0.01%	2867
2024 Q3	–	Sell	-8,880	Closed	-$21.5K	–	2914
2024 Q2	$21.5K	Buy	8,880 +6,484	+271%	+$20.6K	﹤0.01%	2765
2024 Q1	$9.7K	Sell	2,396 -31,509	-93%	-$119K	﹤0.01%	3514
2023 Q4	$130K	Buy	+33,905	New	+$101K	﹤0.01%	3119
2023 Q3	–	Sell	-13,116	Closed	-$63.1K	–	3262
2023 Q2	$63.1K	Sell	13,116 -1,783	-12%	-$8.54K	﹤0.01%	3067
2023 Q1	$60.5K	Sell	14,899 -3,093	-17%	-$16.2K	﹤0.01%	3533
2022 Q4	$97.2K	Sell	17,992 -4,950	-22%	-$33.3K	﹤0.01%	3807
2022 Q3	$230K	Sell	22,942 -966	-4%	-$5.54K	﹤0.01%	3678
2022 Q2	$112K	Buy	23,908 +18,521	+344%	+$69.6K	﹤0.01%	3935
2022 Q1	$21K	Sell	5,387 -6,158	-53%	-$33.5K	﹤0.01%	3472
2021 Q4	$78K	Buy	+11,545	New	+$127K	﹤0.01%	3247

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Cubist Systematic Strategies's ABOS Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Acumen Pharmaceuticals (ABOS) in Q3 2025: 23,904 shares worth $40.9K. The stake represents ﹤0.01% of the portfolio and ranks #2867 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ABOS as recently as Q2 2024.

Cubist Systematic Strategies first reported a position in ABOS in Q4 2021 and has held it in 11 quarters since. The position peaked at $230K in Q3 2022. 69 funds tracked by Wall St. Rank hold ABOS as of Q3 2025.

Cubist Systematic Strategies held 23,904 shares of Acumen Pharmaceuticals worth $40.9K as of Q3 2025.
Acumen Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
Acumen Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2867 holding.
Cubist Systematic Strategies first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Cubist Systematic Strategies's Acumen Pharmaceuticals position peaked at $230K in Q3 2022.
69 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.